Business Context and Reporting Period
This Form 8-K Current Report was filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on June 23, 2016, covering events occurring on June 21, 2016. The Company is incorporated in Delaware and headquartered in Carlsbad, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
On June 21, 2016, the Board of Directors approved an amendment to the Company's Bylaws to implement a forum selection provision. This amendment designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for:
- Derivative actions or proceedings brought on behalf of the Company.
- Actions asserting claims of breach of fiduciary duty by directors, officers, or employees.
- Actions arising under the Delaware General Corporation Law, the Certificate of Incorporation, or the Bylaws.
- Actions governed by the internal affairs doctrine.
This provision applies unless the Company consents in writing to an alternative forum.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed relates to the limitation of legal venues for stockholder litigation, restricting such actions to the Delaware Court of Chancery.
Investor Verification Checklist
- Verify the correct registrant name is Signal Genetics, Inc., as the input metadata referenced Viridian Therapeutics, Inc.
- Confirm the effective date of the Bylaw Amendment is June 21, 2016.
- Review Exhibit 3.1 (Amendment to Bylaws) for the full legal text of the forum selection clause.
- Check subsequent filings for any financial data, as this 8-K contains none.